{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:54Z","timestamp":1777870374566,"version":"3.51.4"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Metabolic Bone Disease in CKD Patients Research Unit, Faculty of Medicine, Chulalongkorn University, Thailand","award":["GRU6201230005-1"],"award-info":[{"award-number":["GRU6201230005-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40620-021-01065-3","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T09:06:03Z","timestamp":1622538363000},"page":"473-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"35","author":[{"given":"Jeerath","family":"Phannajit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natthaphon","family":"Wonghakaeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kullaya","family":"Takkavatakarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanin","family":"Asawavichienjinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kearkiat","family":"Praditpornsilpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somchai","family":"Eiam-Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9813-9219","authenticated-orcid":false,"given":"Paweena","family":"Susantitaphong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"3","key":"1065_CR1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z (2018) Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 94(3):567\u2013581","journal-title":"Kidney Int"},{"issue":"17","key":"1065_CR2","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108(17):2154\u20132169","journal-title":"Circulation"},{"issue":"2","key":"1065_CR3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000197562","volume":"27","author":"M Kanbay","year":"2009","unstructured":"Kanbay M, Goldsmith D, Akcay A, Covic A (2009) Phosphate\u2014the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 27(2):220\u2013230","journal-title":"Blood Purif"},{"issue":"8","key":"1065_CR4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15(8):2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"1065_CR5","first-page":"S1","volume":"113","author":"Kidney Disease Improving Global Outcomes CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease Improving Global Outcomes CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1-130","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"1065_CR6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","volume":"11","author":"L Patel","year":"2016","unstructured":"Patel L, Bernard LM, Elder GJ (2016) Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 11(2):232\u2013244","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1065_CR7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","volume":"68","author":"SC Palmer","year":"2016","unstructured":"Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, French R, Ruospo M, Strippoli GF (2016) Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis 68(5):691\u2013702","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1065_CR8","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","volume":"11","author":"N Sekercioglu","year":"2016","unstructured":"Sekercioglu N, Thabane L, D\u00edaz Mart\u00ednez JP, Nesrallah G, Longo CJ, Busse JW, Akhtar-Danesh N, Agarwal A, Al-Khalifah R, Iorio A, Guyatt GH (2016) Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS One 11(6):e0156891","journal-title":"PLoS One"},{"issue":"3","key":"1065_CR9","doi-asserted-by":"crossref","first-page":"e0171028","DOI":"10.1371\/journal.pone.0171028","volume":"12","author":"N Sekercioglu","year":"2017","unstructured":"Sekercioglu N, Angeliki Veroniki A, Thabane L, Busse JW, Akhtar-Danesh N, Iorio A, Cruz Lopes L, Guyatt GH (2017) Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: a systematic review and NMA. PLoS One 12(3):e0171028","journal-title":"PLoS One"},{"issue":"1","key":"1065_CR10","first-page":"111","volume":"32","author":"S Habbous","year":"2017","unstructured":"Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J (2017) The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 32(1):111\u2013125","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1065_CR11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/0148607117715440","volume":"42","author":"X Yang","year":"2018","unstructured":"Yang X, Bai Q, Li Y, Liu H, Guo H, Zhang X (2018) Comparative efficacy and safety of phosphate binders in hyperphosphatemia patients with chronic kidney disease. JPEN J Parenter Enteral Nutr 42(4):766\u2013777","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"2","key":"1065_CR12","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000488700","volume":"43","author":"F Wang","year":"2018","unstructured":"Wang F, Lu X, Zhang J, Xiong R, Li H, Wang S (2018) Effect of lanthanum carbonate on all-cause mortality in patients receiving maintenance hemodialysis: a meta-analysis of randomized controlled trials. Kidney Blood Press Res 43(2):536\u2013544","journal-title":"Kidney Blood Press Res"},{"key":"1065_CR13","doi-asserted-by":"publisher","unstructured":"Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GFM (2018) Phosphate binders for preventing and treating chronic kidney disease\u2010mineral and bone disorder (CKD\u2010MBD). Cochrane Database Syst Rev 8. https:\/\/doi.org\/10.1002\/14651858.CD006023.pub3","DOI":"10.1002\/14651858.CD006023.pub3"},{"issue":"2","key":"1065_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","volume":"10","author":"SK Burke","year":"2003","unstructured":"Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JMJA (2003) Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 10(2):133\u2013145","journal-title":"Adv Ren Replace Ther"},{"issue":"10","key":"1065_CR15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3109\/0886022X.2013.828365","volume":"35","author":"H Guo","year":"2013","unstructured":"Guo H, Zhang X, Tang S, Zhang SJRF (2013) Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis-system review of lanthanum carbonate. Ren Fail 35(10):1455\u20131464","journal-title":"Ren Fail"},{"issue":"1","key":"1065_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1185\/03007995.2013.838551","volume":"30","author":"W Huang","year":"2014","unstructured":"Huang W, Liu J, Tang Y, Gao X, Di B, Zhang F (2014) Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis\u2014a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 30(1):99\u2013108","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1065_CR17","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/ndt\/gfp350","volume":"24","author":"SA Jamal","year":"2009","unstructured":"Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT (2009) The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 24(10):3168\u20133174","journal-title":"Nephrol Dial Transplant"},{"issue":"9900","key":"1065_CR18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","volume":"382","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268\u20131277","journal-title":"Lancet"},{"issue":"8","key":"1065_CR19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3109\/0886022X.2014.938544","volume":"36","author":"L Liu","year":"2014","unstructured":"Liu L, Wang Y, Chen H, Zhu X, Zhou L, Yang Y (2014) The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail 36(8):1244\u20131252","journal-title":"Ren Fail"},{"issue":"3","key":"1065_CR20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","volume":"66","author":"B Manns","year":"2004","unstructured":"Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66(3):1239\u20131247","journal-title":"Kidney Int"},{"issue":"4","key":"1065_CR21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","volume":"54","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF (2009) Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 54(4):619\u2013637","journal-title":"Am J Kidney Dis"},{"key":"1065_CR22","doi-asserted-by":"publisher","unstructured":"Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2. https:\/\/doi.org\/10.1002\/14651858.CD006023.pub2","DOI":"10.1002\/14651858.CD006023.pub2"},{"issue":"10","key":"1065_CR23","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/ndt\/gfm421","volume":"22","author":"M Tonelli","year":"2007","unstructured":"Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B (2007) Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 22(10):2856\u20132866","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1065_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s11255-017-1774-9","volume":"50","author":"D Xie","year":"2018","unstructured":"Xie D, Ye N, Li M (2018) A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients. Int Urol Nephrol 50(5):905\u2013909","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"1065_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/0886022X.2014.976160","volume":"37","author":"C-J Zhai","year":"2015","unstructured":"Zhai C-J, Yu X-S, Yang X-W, Sun J, Wang R (2015) Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis. Ren Fail 37(1):7\u201315","journal-title":"Ren Fail"},{"issue":"1","key":"1065_CR26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2369-14-226","volume":"14","author":"C Zhang","year":"2013","unstructured":"Zhang C, Wen J, Li Z, Fan J (2013) Efficacy and safety of lanthanum carbonate on chronic kidney disease\u2014mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14(1):226\u2013239","journal-title":"BMC Nephrol"},{"issue":"4","key":"1065_CR27","doi-asserted-by":"crossref","first-page":"c259","DOI":"10.1159\/000313484","volume":"115","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Li M, Lu Y, Li H, Gu Y, Hao C, Chen J (2010) Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 115(4):c259-267","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"1065_CR28","first-page":"466","volume":"27","author":"F Caravaca","year":"2007","unstructured":"Caravaca F, Ruiz AB, Escola JM, Hern\u00e1ndez Gallego R, Cerezo I, Fern\u00e1ndez N, Barroso S, Mart\u00edn MV (2007) Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients. Nefrologia 27(4):466\u2013471","journal-title":"Nefrologia"},{"issue":"1","key":"1065_CR29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1744-9987.2010.00868.x","volume":"15","author":"V Filiopoulos","year":"2011","unstructured":"Filiopoulos V, Koutis I, Trompouki S, Hadjiyannakos D, Lazarou D, Vlassopoulos D (2011) Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Ther Apher Dial 15(1):20\u201327","journal-title":"Ther Apher Dial"},{"issue":"3","key":"1065_CR30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CN108227","volume":"82","author":"KR Phelps","year":"2014","unstructured":"Phelps KR, Stote KS, Mason D (2014) Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism. Clin Nephrol 82(3):191\u2013201","journal-title":"Clin Nephrol"},{"issue":"4","key":"1065_CR31","doi-asserted-by":"crossref","first-page":"c278","DOI":"10.1159\/000127361","volume":"108","author":"T Takei","year":"2008","unstructured":"Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, Akiba T, Nitta K (2008) Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract 108(4):c278-283","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"1065_CR32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","volume":"24","author":"P Evenepoel","year":"2009","unstructured":"Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S (2009) Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 24(1):278\u2013285","journal-title":"Nephrol Dial Transplant"},{"key":"1065_CR33","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","volume":"85","author":"JG Hervas","year":"2003","unstructured":"Hervas JG, Prados D, Cerezo S (2003) Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int Suppl 85:S69-72","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"1065_CR34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","volume":"8","author":"RP W\u00fcthrich","year":"2013","unstructured":"W\u00fcthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8(2):280\u2013289","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1065_CR35","first-page":"785","volume":"25","author":"FA Shaheen","year":"2004","unstructured":"Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ (2004) Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 25(6):785\u2013791","journal-title":"Saudi Med J"},{"issue":"Suppl 1","key":"1065_CR36","first-page":"17","volume":"18","author":"K Tan","year":"2013","unstructured":"Tan K, Raman P, Petrie J (2013) The SLO-NIACIN Trial: a double-blind placebo controlled randomised cross-over trial of low dose slow-release niacin to lower phosphate in haemodialysis patients [ANZSN Abstract no.010]. Nephrology 18(Suppl 1):17","journal-title":"Nephrology"},{"issue":"8","key":"1065_CR37","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","volume":"20","author":"HG Asmus","year":"2005","unstructured":"Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J (2005) Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20(8):1653\u20131661","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1065_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","volume":"62","author":"J Braun","year":"2004","unstructured":"Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J (2004) Long-term comparison of a calcium-free phosphate binder and calcium carbonate\u2013phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62(2):104\u2013115","journal-title":"Clin Nephrol"},{"issue":"5","key":"1065_CR39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000072822","volume":"23","author":"GM Chertow","year":"2003","unstructured":"Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD (2003) The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23(5):307\u2013314","journal-title":"Am J Nephrol"},{"issue":"4","key":"1065_CR40","first-page":"284","volume":"70","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC (2008) Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70(4):284\u2013295","journal-title":"Clin Nephrol"},{"key":"1065_CR41","doi-asserted-by":"crossref","unstructured":"St Peter WL, Liu J, Weinhandl E, Fan Q (2008) A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the dialysis clinical outcomes revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51(3):445\u2013454","DOI":"10.1053\/j.ajkd.2007.12.002"},{"issue":"1","key":"1065_CR42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62(1):245\u2013252","journal-title":"Kidney Int"},{"issue":"3","key":"1065_CR43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CNP65191","volume":"65","author":"WF Finn","year":"2006","unstructured":"Finn WF (2006) Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65(3):191\u2013202","journal-title":"Clin Nephrol"},{"issue":"9","key":"1065_CR44","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","volume":"72","author":"WN Suki","year":"2007","unstructured":"Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72(9):1130\u20131137","journal-title":"Kidney Int"},{"key":"1065_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"1065_CR46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"key":"1065_CR47","first-page":"10","volume":"1","author":"M Gordon","year":"2020","unstructured":"Gordon M, Lumley T (2020) forestplot: advanced Forest Plot Using \u201cgrid\u201d Graphics. R package version 1:10","journal-title":"R package version"},{"key":"1065_CR48","unstructured":"R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna."},{"issue":"6","key":"1065_CR49","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1681\/ASN.2016080855","volume":"28","author":"GA Block","year":"2017","unstructured":"Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Astrand M, Johansson S, Knutsson M, Langkilde AM, Chertow GM (2017) Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol 28(6):1933\u20131942","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1065_CR50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","volume":"30","author":"GA Block","year":"2019","unstructured":"Block GA, Rosenbaum DP, Yan A, Chertow GM (2019) Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol 30(4):641\u2013652","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1065_CR51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1755-6686.2013.12009.x","volume":"39","author":"SP Chennasamudram","year":"2013","unstructured":"Chennasamudram SP, Noor T, Vasylyeva TL (2013) Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. J Ren Care 39(2):82\u201389","journal-title":"J Ren Care"},{"issue":"suppl 9","key":"1065_CR52","first-page":"S108","volume":"19","author":"NG De Santo","year":"2006","unstructured":"De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M (2006) Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 19(suppl 9):S108-114","journal-title":"J Nephrol"},{"issue":"6","key":"1065_CR53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","volume":"7","author":"H Vlassara","year":"2012","unstructured":"Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE (2012) Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7(6):934\u2013942","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1065_CR54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1744-9987.2012.01071.x","volume":"16","author":"S Kasai","year":"2012","unstructured":"Kasai S, Sato K, Murata Y, Kinoshita Y (2012) Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Ther Apher Dial 16(4):341\u2013349","journal-title":"Ther Apher Dial"},{"issue":"6","key":"1065_CR55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","volume":"30","author":"JH Ix","year":"2019","unstructured":"Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP et al (2019) Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE Trial. J Am Soc Nephrol 30(6):1096\u20131108","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1065_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN106830","volume":"78","author":"RS Kalil","year":"2012","unstructured":"Kalil RS, Flanigan M, Stanford W, Haynes WG (2012) Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. Clin Nephrol 78(1):1\u20139","journal-title":"Clin Nephrol"},{"issue":"1","key":"1065_CR57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1525-139X.2011.00849.x","volume":"24","author":"JT Daugirdas","year":"2011","unstructured":"Daugirdas JT, Finn WF, Emmett M, Chertow GM (2011) The phosphate binder equivalent dose. Semin Dial 24(1):41\u201349","journal-title":"Semin Dial"},{"issue":"3","key":"1065_CR58","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11914-017-0368-x","volume":"15","author":"KM Hill Gallant","year":"2017","unstructured":"Hill Gallant KM, Spiegel DM (2017) Calcium balance in chronic kidney disease. Curr Osteoporos Rep 15(3):214\u2013221","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"1065_CR59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","volume":"18","author":"T Sadek","year":"2003","unstructured":"Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A (2003) Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18(3):582\u2013589","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1065_CR60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","volume":"62","author":"B Di Iorio","year":"2013","unstructured":"Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62(4):771\u2013778","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1065_CR61","first-page":"870","volume":"32","author":"A Lenglet","year":"2017","unstructured":"Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel A-S, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA (2017) Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 32(5):870\u2013879","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1065_CR62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000325656","volume":"34","author":"B Di Iorio","year":"2011","unstructured":"Di Iorio B, Nargi O, Cucciniello E, Bellizzi V, Torraca S, Russo D, Bellasi A (2011) Coronary artery calcification progression is associated with arterial stiffness and cardiac repolarization deterioration in hemodialysis patients. Kidney Blood Press Res 34(3):180\u2013187","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"1065_CR63","first-page":"694","volume":"22","author":"BR Di Iorio","year":"2009","unstructured":"Di Iorio BR, Cucciniello E, Bellizzi V (2009) Vascular calcification and QT interval in incident hemodialysis patients. J Nephrol 22(6):694\u2013698","journal-title":"J Nephrol"},{"issue":"2","key":"1065_CR64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MAJ.0b013e3181815498","volume":"337","author":"HJ Hsu","year":"2009","unstructured":"Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337(2):116\u2013122","journal-title":"Am J Med Sci"},{"issue":"1","key":"1065_CR65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000339026","volume":"36","author":"A Unsal","year":"2012","unstructured":"Unsal A, Kose Budak S, Koc Y, Basturk T, Sakaci T, Ahbap E, Sinangil A (2012) Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. Kidney Blood Press Res 36(1):55\u201364","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"1065_CR66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M (2014) Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25(2):349\u2013360","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1065_CR67","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MA Mirza","year":"2009","unstructured":"Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205(2):385\u2013390","journal-title":"Atherosclerosis"},{"issue":"3","key":"1065_CR68","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","volume":"91","author":"J Munoz Mendoza","year":"2017","unstructured":"Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M, Investigators CS (2017) Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 91(3):711\u2013719","journal-title":"Kidney Int"},{"key":"1065_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02848-0[Inpress]","author":"K Takkavatakarn","year":"2021","unstructured":"Takkavatakarn K, Wuttiputhanun T, Phannajit J, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P (2021) Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-021-02848-0[Inpress]","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"1065_CR70","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","volume":"7","author":"B Di Iorio","year":"2012","unstructured":"Di Iorio B, Bellasi A, Russo D (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 7(3):487\u2013493","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1065_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN107630","volume":"80","author":"MM Lemos","year":"2013","unstructured":"Lemos MM, Watanabe R, Carvalho AB, Jancikic AD, Sanches FM, Christofalo DM, Draibe SA, Canziani ME (2013) Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clin Nephrol 80(1):1\u20138","journal-title":"Clin Nephrol"},{"issue":"5","key":"1065_CR72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2215\/CJN.07750814","volume":"10","author":"EM Yubero-Serrano","year":"2015","unstructured":"Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE (2015) Effects of sevelamer carbonate on advanced glycation end products and antioxidant\/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol 10(5):759\u2013766","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1065_CR73","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","volume":"72","author":"D Russo","year":"2007","unstructured":"Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72(10):1255\u20131261","journal-title":"Kidney Int"},{"issue":"5","key":"1065_CR74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","volume":"24","author":"CD Chue","year":"2013","unstructured":"Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, Edwards NC, Steeds RP, Ferro CJ (2013) Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24(5):842\u2013852","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1065_CR75","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23(8):1407\u20131415","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1065_CR76","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10157-017-1504-8","volume":"22","author":"E Riccio","year":"2018","unstructured":"Riccio E, Sabbatini M, Bruzzese D, Grumetto L, Marchetiello C, Amicone M, Andreucci M, Guida B, Passaretti D, Russo G, Pisani A (2018) Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clin Exp Nephrol 22(3):529\u2013538","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1065_CR77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2215\/CJN.02810707","volume":"3","author":"K Caglar","year":"2008","unstructured":"Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P (2008) Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3(1):61\u201368","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1065_CR78","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5(2):286\u2013291","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1065_CR79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","volume":"59","author":"MI Yilmaz","year":"2012","unstructured":"Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C (2012) Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 59(2):177\u2013185","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"1065_CR80","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342(20):1478\u20131483","journal-title":"N Engl J Med"},{"key":"1065_CR81","doi-asserted-by":"crossref","unstructured":"Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, Ross W, Windus D, Davila-Roman VG, Hruska KA (2013) Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 38(2):158\u2013167","DOI":"10.1159\/000353569"},{"issue":"11","key":"1065_CR82","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1681\/ASN.2020040411","volume":"31","author":"ND Toussaint","year":"2020","unstructured":"Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi L-S, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM (2020) A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol 31(11):2653\u20132666","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-01065-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:58Z","timestamp":1777564558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/2\/473\/8326105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-01065-3","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declared no competing interests. All authors have completed the ICMJE uniform disclosure form for Disclosure of Potential Conflicts of Interest and none were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This meta-analysis involving synthesis of secondary data is exempt from ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}}]}}